Physician profile
Peter Malamas
NPI 1023500477
$1,400.48
in general payments reported to CMS, 2019-2025
10 companies · $126 in 2025
The $126 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $319 · 2023: $317 · 2024: $514 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.97 | 2022-2024 | Jardiance |
| Amgen INC. | $278.48 | 2021-2024 | Repatha |
| Medtronic, INC. | $234.12 | 2023-2024 | Corevalve Evolut R, Symplicity G3 |
| Janssen Pharmaceuticals, INC | $197.01 | 2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $136.19 | 2024-2025 | Lifevest |
| Astellas Pharma US INC | $122.21 | 2021-2022 | |
| Chiesi USA, INC. | $49.45 | 2022-2023 | Kengreal |
| Actelion Pharmaceuticals US, INC. | $30.63 | 2024 | Uptravi, Opsumit |
| Lantheus Medical Imaging, INC. | $30.55 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $14.87 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Malamas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.